Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL771731 | 0.79 | — | — | |
| SCHEMBL9033590 | 0.77 | SMN1; SMN2 (0.37) | CA2 | |
| SCHEMBL7409342 | 0.77 | PDF (0.41) | — | |
| SCHEMBL3458099 | 0.72 | CA2 (0.37) | CA2ALDH1A1MAPTPTGS1 | |
| SCHEMBL28479550 | 0.72 | CA2 (0.37) | CA2ALDH1A1MAPTPTGS1 | |
| SCHEMBL3458098 | 0.72 | CA2 (0.37) | CA2ALDH1A1MAPTPTGS1 | |
| SCHEMBL88565 | 0.72 | CA2 (0.37) | CA2ALDH1A1MAPTPTGS1 | |
| SCHEMBL10519395 | 0.70 | CA2 (0.40) | CA2ALDH1A1MAPTPTGS1 | |
| SCHEMBL2422937 | 0.70 | CA2 (0.36) | CA2ALDH1A1MAPTPTGS1 | |
| SCHEMBL18799755 | 0.70 | CA2 (0.40) | CA2ALDH1A1MAPTPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| EP-1719773-B1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-0705835-A1 | Quinoxalic-2,3-diones with an oxa or thiaheterocyclic fused ring | CIBA-GEIGY AG (CH) | 1996-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | CA2 2701/4885ALDH1A1 750/4885MAPT 3389/4885 |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | CA2 4553/4885ALDH1A1 351/4885MAPT 3246/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | CA2 2701/4885ALDH1A1 750/4885MAPT 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.